Valaciclovir
300px | |
Systematic (IUPAC) name | |
---|---|
(S)-2-[(2-amino-6-oxo-6,9-dihydro-3H-purin-9-yl)methoxy]ethyl-2-amino-3-methylbutanoate | |
Clinical data | |
Pregnancy category | |
Routes of administration | Oral |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 55% |
Protein binding | 13–18% |
Metabolism | Hepatic (to aciclovir) |
Biological half-life |
<30 minutes (valaciclovir); 2.5-3.6 hours (aciclovir) |
Excretion |
Renal 40–50% (aciclovir), faecal 47% (aciclovir) |
Identifiers | |
CAS Number | 124832-26-4 |
ATC code | J05AB11 (WHO) |
PubChem | CID 60773 |
DrugBank | APRD00697 |
ChemSpider | 54770 |
Chemical data | |
Formula | C13H20N6O4 |
Molar mass | 324.336 g/mol[[Script error: No such module "String".]] |
Script error: No such module "collapsible list". |
Valaciclovir (INN) or valacyclovir (USAN) is an antiviral drug used in the management of herpes simplex and herpes zoster (shingles). It is a prodrug, being converted in vivo to aciclovir. It is marketed by GlaxoSmithKline under the trade name Valtrex or Zelitrex. As of November 25, 2009[update], Valacyclovir is being marketed in generic form in the United States by Ranbaxy Laboratories.[1]
Contents
Chemistry
Valaciclovir is prepared, starting from the natural proteinogenic amino acid (L)-valine.
Pharmacology
Mechanism of action
This section does not cite any references or sources. Please help improve this section by adding citations to reliable sources. Unsourced material may be challenged and removed. (January 2010) |
Valaciclovir is a prodrug, an esterified version of aciclovir that has greater oral bioavailability (about 55%) than aciclovir (10-20%). It is converted by esterases to the active drug aciclovir, as well as the amino acid valine, via hepatic first-pass metabolism. Acyclovir is selectively converted into a monophosphate form by viral thymidine kinase, which is far more effective (3000 times) in phosphorylation than cellular thymidine kinase. Subsequently, the monophosphate form is further phosphorylated into the active triphosphate form, aciclo-GTP, by cellular kinases. Aciclo-GTP is a very potent inhibitor of viral DNA polymerase; it has approximately 100 times higher affinity to viral than cellular polymerase. Its monophosphate form also incorporates into the viral DNA, resulting in chain termination. It has also been shown that the viral enzymes cannot remove aciclo-GMP from the chain, which results in inhibition of further activity of DNA polymerase. Aciclo-GTP is fairly rapidly metabolised within the cell, possibly by cellular phosphatases.
Microbiology
Aciclovir, the active metabolite of valaciclovir, is active against most species in the herpesvirus family. In descending order of activity:[2]
- Herpes simplex virus type I (HSV-1)
- Herpes simplex virus type II (HSV-2)
- Varicella zoster virus (VZV)
- Epstein-Barr virus (EBV)
- Cytomegalovirus (CMV)
Activity is predominantly active against HSV, and to a lesser extent VZV. It is only of limited efficacy against EBV and CMV, however, valacyclovir has recently been shown to lower or eliminate the presence of the Epstein-Barr virus in subjects afflicted with acute mononucleosis, leading to a significant decrease in the severity of symptoms.[3][4][5] It is inactive against latent viruses in nerve ganglia.
To date[when?], resistance to valaciclovir has not been clinically significant. Mechanisms of resistance in HSV include deficient viral thymidine kinase; and mutations to viral thymidine kinase and/or DNA polymerase, altering substrate sensitivity.[6]
Ingredients
Valtrex is offered in 500 mg and 1 gram tablets, the active ingredient being valacyclovir hydrochloride, with the inactive ingredients carnauba wax, colloidal silicon dioxide, crospovidone, FD&C Blue No. 2 Lake, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, povidone, and titanium dioxide.[7]
Clinical use
Indications
Valaciclovir is indicated for the treatment of HSV and VZV infections, including:[8]
- Oral and Genital herpes simplex (treatment and prophylaxis)
- Reduction of HSV transmission from people with recurrent infection to uninfected individuals
- Herpes zoster (shingles)
- Prevention of CMV disease following organ transplantation
- Prophylaxis against herpesvirus' in immunocompromised patients (such as patients undergoing cancer chemotherapy)
It has shown promise as a treatment for infectious mononucleosis[3][4][9] and is preventatively administered in suspected cases of Herpes B Virus exposure.
Adverse effects
Common adverse drug reactions (≥1% of patients) associated with valaciclovir therapy are the same as for aciclovir, its active metabolite, and include: nausea, vomiting, diarrhea and headache. Infrequent adverse effects (0.1–1% of patients) include: agitation, vertigo, confusion, dizziness, edema, arthralgia, sore throat, constipation, abdominal pain, rash, weakness and/or renal impairment. Rare adverse effects (<0.1% of patients) include: coma, seizures, neutropenia, leukopenia, tremor, ataxia, encephalopathy, psychotic symptoms, crystalluria, anorexia, fatigue, hepatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis and/or anaphylaxis.[8]
References
Cite error: Invalid <references>
tag;
parameter "group" is allowed only.
<references />
, or <references group="..." />
es:Valaciclovir fr:Valaciclovir it:Valaciclovir ja:バラシクロビル sv:Valaciklovir th:วาลาไซโคลเวียร์
zh:伐昔洛韦- ↑ Ahmed, Rumman (2009-11-27). "Ranbaxy Launches Generic Valtrex in U.S." (subscription required). The Wall Street Journal. Retrieved 2010-01-16.
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- ↑ 3.0 3.1 Balfour et al. (December 2005) A controlled trial of valacyclovir in infectious mononucleosis. Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC., December 18, 2005. Abstract V1392
- ↑ 4.0 4.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- ↑ Sweetman, Sean C., ed. (2005). Martindale: the complete drug reference (34th ed.). London: Pharmaceutical Press. ISBN 0-85369-550-4. OCLC 56903116.[page needed]
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- ↑ 8.0 8.1 Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3[page needed]
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Articles containing potentially dated statements from November 2009
- Articles with invalid date parameter in template
- All articles containing potentially dated statements
- Articles needing additional references from January 2010
- All articles needing additional references
- Vague or ambiguous time from January 2010
- 2Fix
- Antivirals
- Prodrugs
- GlaxoSmithKline
- Purines
- Ethers
- Amino acid derivatives
- Carboxylate esters
- Wikipedia articles needing page number citations from September 2010